Prostate Cancer Drugs
Jul 15, 2025
Nanoscope’s MCO-010 Begins FDA Rolling Submission for Retinitis Pigmentosa; Bayer’s KERENDIA Approved by FDA for Heart Failure With Preserved Ejection Fraction; Klotho Neurosciences’ KLTO-202 Receives FDA Orphan Drug Designation for ALS; Trethera’s TRE-515 Granted FDA Fast Track Designation for Metastatic Prostate Cancer; Adcentrx’s ADRX-0405 Awarded FDA Orphan Drug Designation for Gastric Cancer
Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa Nanoscope Therapeutics has initiated a rolling submission of its Biologics License Application (BLA) to the FDA for MCO-010, a first-in-class, gene-agnostic optogenetic therapy targeting severe vision loss due to retinitis p...
Read More...
Oct 11, 2024
12 Breakthrough Prostate Cancer Drugs in Late-Stage Development
Prostate cancer is one of the most common cancers among men, affecting about 1 in 8 men in the United States at some point in their lives. According to estimates from DelveInsight, there were nearly 8.2 million total cases of prostate cancer in the 7MM in 2023, although this number does not indicate how many of the...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
